Ignite Creation Date:
2024-05-06 @ 4:11 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04900363
Status:
UNKNOWN
Last Update Posted:
2022-10-12
First Post:
2021-04-29
Brief Title:
A Trial of AK112 PD-1VEGF Bispecific Antibody in Patients With NSCLC
Sponsor:
Akeso
Organization:
Akeso
Study Overview
Official Title:
A Phase IbII Trial of AK112 PD-1VEGF Bispecific Antibody in Patients With Advanced NSCLC
Status:
UNKNOWN
Status Verified Date:
2022-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is a Phase IbII study All patients are stage IIIBC or IV non-small cell lung cancerNSCLC Eastern Cooperative Oncology Group ECOG performance status 0-1 The purpose of this study is to evaluate the efficacy and safety of AK112 in subjects with advanced NSCLC whose tumors have a programmed cell death-ligand 1 PD-L1 Tumor Proportion Score TPS greater than or equal to 1
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None